Last reviewed · How we verify
Gliclazide MR and Insulin Glargine Injection
Gliclazide MR and Insulin Glargine Injection, marketed by Servier (Tianjin) Pharmaceutical Co. LTD., is a combination therapy currently available in the market. The key composition patent is set to expire in 2028, providing a period of exclusivity and potential revenue stability. The primary risk is the lack of reported key trial results and revenue data, which may limit the drug's competitive positioning and investor confidence.
At a glance
| Generic name | Gliclazide MR and Insulin Glargine Injection |
|---|---|
| Also known as | Brand Name: Diamicron MR and Lantus |
| Sponsor | Servier (Tianjin) Pharmaceutical Co. LTD. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat Type 2 Diabetes (PHASE4)
- Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: